Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Body Composition Analysis in Young Patients with Recent Diagnosis of Multiple Sclerosis: An Exploratory Study.

Journal of clinical medicineยท2026
Same author

Optic nerve involvement in multiple sclerosis diagnosis - Authors' reply.

The Lancet. Neurologyยท2026
Same author

AEGIS reveals epitope- and clone-resolved convergence of CNS B and T cell autoreactivity in ROHHAD.

bioRxiv : the preprint server for biologyยท2026
Same author

Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis.

The Lancet. Neurologyยท2026
Same author

Predicting multiple sclerosis from radiologically isolated syndrome using generative artificial intelligence.

PLOS digital healthยท2026
Same author

Longitudinal Cortical Surface Signatures Distinguish Neuromyelitis Optica Spectrum Disorder from Multiple Sclerosis.

AJNR. American journal of neuroradiologyยท2026

Related Experiment Video

Updated: Jun 4, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

Tamara Castillo-Trivino1, Ellen M Mowry, Alberto Gajofatto

  • 1Multiple Sclerosis Center, Department of Neurology, University of California San Francisco, San Francisco, California, USA.

Plos One
|February 10, 2011
PubMed
Summary

Switching multiple sclerosis patients with breakthrough disease to natalizumab or immunosuppressants significantly reduced relapse rates. This study highlights effective treatment options for managing active relapsing MS.

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Related Experiment Videos

Last Updated: Jun 4, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Area of Science:

  • Neurology
  • Immunology
  • Clinical Trials

Background:

  • Multiple sclerosis (MS) patients experiencing breakthrough disease on immunomodulatory drugs often transition to natalizumab or immunosuppressants.
  • The efficacy of natalizumab monotherapy in this specific patient group remains largely uncharacterized.

Purpose of the Study:

  • To evaluate the effectiveness of switching to natalizumab or immunosuppressants in multiple sclerosis patients with breakthrough disease.
  • To compare relapse rates before and after treatment modification in different patient groups.

Main Methods:

  • An open-label retrospective cohort study involving 993 patients at the University of California San Francisco MS Center.
  • Analysis of 95 patients with breakthrough disease: 60 switched to natalizumab, 22 to immunosuppressants, and 13 did not switch.
  • Poisson regression was used to compare relapse rates, adjusting for potential confounders.

Main Results:

  • Relapse rates decreased significantly: 70% in natalizumab switchers and 77% in immunosuppressant switchers.
  • No significant decrease in relapse rate was observed in non-switchers (6% reduction).
  • Compared to non-switchers, natalizumab switchers showed a 68% reduction in relapse rate, and immunosuppressant switchers showed a 76% reduction.

Conclusions:

  • Switching to natalizumab or immunosuppressants is effective for reducing clinical activity in relapsing MS patients with breakthrough disease.
  • Further evaluation of the risk-benefit ratio and efficacy is warranted through randomized clinical trials and prospective studies.